©2022 Stanford Medicine
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Trial ID: NCT01492101
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Inclusion Criteria (major highlights):
- Patient is an adult female with histologically or cytologically confirmed carcinoma of
the breast for whom single-agent cytotoxic chemotherapy is indicated
- Patient can have either measurable or non-measurable disease by RECIST.
- Patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or
metastatic setting) with an anthracycline, a taxane and capecitabine
- Patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with
the last dose administered within 6 months. A minimum of two chemotherapy regimens had
to be for locally recurrent and/or metastatic disease. All therapy received prior to a
diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant
therapy following a second resection) is counted as one regimen.
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematopoietic, liver and kidney functions.
Exclusion Criteria (major highlights):
- Patient with chemotherapy within 21 days, radiotherapy within 14 days, biological
therapy with 14 days, hormonal therapy within 7 days and investigational therapy
within 21 days prior to randomization.
- Patient with any major surgery within 28 days prior to randomization.
- Patient with concurrent use of biologic agents for the treatment of cancer including
antibodies or any investigational agent(s).
- Patient with prior treatment for cancer with a camptothecin derivative.
- Patient with chronic or acute GI disorders resulting in diarrhea of any severity
grade; patients who are using chronic anti-diarrheal supportive care to control
diarrhea in the 28 days prior to randomization.
- Patient received pharmacotherapy for hepatitis B or C, tuberculosis or HIV.
- Patient with known cirrhosis diagnosed with Child-PUGH Class A or higher liver
- Patient with prior malignancy (other than breast cancer) except for non-melanoma skin
cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and
definitively treated more than 5 years prior to randomization.
- Patient requiring daily use of oxygen supplementation in the 28 days prior to
- Patients with significant cardiovascular impairment.
drug: Treatment of Physician's Choice (TPC)
School of Medicine
300 Pasteur Drive
Stanford, CA 94305